cobas^® Cdiff

Limit the speed of infection

Clostridioides difficile (C. diff) is the most common healthcare-associated infection, causing antibiotic-associated diarrhea that may lead to pseudomembranous colitis and even death. C. diff has an enormous impact on healthcare systems worldwide. An estimated 124,000¹ cases of Clostridioides difficile infection (CDI) occur annually in Europe, costing the EU up to €3 billion per year.²

Features and benefits

• Speed and accuracy deliver definitive results with a 20 minute turnaround time to inform timely treatment
• Ease of use with simplified workflow, reduced hands-on time (less than a minute; no vortex or precision pipetting required) and easy result interpretation
• Flexibility & accessibility to take appropriate measures for isolation and prevention to limit the spread of infection.

Intended use

The cobas^® Cdiff Nucleic acid test for use on the cobas^® Liat^® System is an automated, qualitative in vitro diagnostic test that uses real-time polymerase chain reaction (PCR) for the detection of the toxin B (tcdB) gene of toxigenic Clostridioides difficile in unformed (liquid or soft) stool specimens obtained from patients suspected of having C. difficile infection (CDI). The cobas^® Cdiff Nucleic acid test for use on the cobas^® Liat^® System is intended for use as an aid in the diagnosis of CDI in humans in conjunction with clinical and epidemiological risk factors.

The cobas^® Liat^® System is commercially available in select markets. This product is not registered as an in vitro diagnostic (IVD) in all countries; additional information may be available from your Roche sales representative.

Registration status

CE-IVD

Package inserts

Access package inserts through your country’s Roche Diagnostics Website.